by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia
Abstract INTRODUCTION This analysis of the phase 3 TRAILBLAZER-ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p-tau217) level can reliably monitor treatment-related amyloid clearance (TRAC) after donanemab treatment in early...
by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia
Abstract INTRODUCTION Sleep disturbances are frequent symptoms of Alzheimer’s disease (AD), mirrored by early pathology in the dorsal raphe nucleus (DRN). Whether early DRN pathology can drive sleep disturbances, and the relative contributions of serotonin...
by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia
Abstract INTRODUCTION ABBV-916, an anti-amyloid immunotherapy, was evaluated in patients with early Alzheimer’s disease (AD). METHODS This phase 1b/2, double-blind, placebo-controlled study consisted of two stages: multiple ascending dose (Stage A) and dose...
by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Paediatric Neuropsychology
. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | August 7, 2026 Neuro-Paediatric Previous Page
by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Paediatric Neuropsychology
. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | August 7, 2026 Neuro-Paediatric Previous Page
